In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections.
The in vitro activity of HSR-903, an oral quinolone, against 196 recent clinical isolates of respiratory pathogens was evaluated. HSR-903 was 2 to 32 times more active than ofloxacin, ciprofloxacin, and sparfloxacin against Staphylococcus aureus, including methicillin-resistant strains, and Streptococcus pneumoniae and was at least as active as the other quinolones against gram-negative pathogens.
Watanabe
A
A
Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University, Aoba-ku, Sendai, Japan. akiwa@idac.tohoku.ac.jp
Tokue
Y
Y
Takahashi
H
H
Kikuchi
T
T
Kobayashi
T
T
Gomi
K
K
Fujimura
S
S
Nukiwa
T
T
D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000493:pharmacokinetics / Q000494:pharmacology*; D012141:Respiratory Tract Infections / Q000382:microbiology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C106426:olamufloxacin